Mark A Socinski

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.

J Thorac Oncol 2020 Dec 14. Epub 2020 Dec 14.

AdventHealth Cancer Institute, 2501 N Orange Ave, Orlando, FL, 32804, USA.

December 2020

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

Clin Lung Cancer 2021 Jan 18;22(1):6-15.e4. Epub 2020 Sep 18.

Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, Heidelberg, Germany.

View Article and Find Full Text PDF

January 2021

Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.

Authors:

Luwei Tao Ruoyu Miao Tarek Mekhail Jingxin Sun Lingbin Meng Cheng Fang Jian Guan Akriti Jain Yuan Du Amanda Allen Brenda L Rzeszutko Mark A Socinski Chung-Che Chang

Clin Lung Cancer 2020 Jul 15. Epub 2020 Jul 15.

Department of Pathology and Laboratory Medicine, AdventHealth-Orlando, Orlando, FL. Electronic address:

View Article and Find Full Text PDF

July 2020

Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.

Authors:

Mohammad Jahanzeb Huamao M Lin Xiaoyun Pan Yu Yin Yanyu Wu Beth Nordstrom Mark A Socinski

Oncologist 2020 Oct 23;25(10):867-877. Epub 2020 Jul 23.

AdventHealth Hospital Cancer Institute, Orlando, Florida, USA.

View Article and Find Full Text PDF

October 2020

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.

Authors:

Martin Reck Thomas Wehler Francisco Orlandi Naoyuki Nogami Carlo Barone Denis Moro-Sibilot Mikhail Shtivelband Jose Luis González Larriba Jeffrey Rothenstein Martin Früh Wei Yu Yu Deng Shelley Coleman Geetha Shankar Hina Patel Claudia Kelsch Anthony Lee Elisabeth Piault Mark A Socinski

J Clin Oncol 2020 Aug 27;38(22):2530-2542. Epub 2020 May 27.

AdventHealth Cancer Institute, Orlando, FL.

View Article and Find Full Text PDF

August 2020

Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

Authors:

Ashwin Somasundaram Mark A Socinski Liza C Villaruz

Drugs 2020 Jun;80(9):883-892

Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

June 2020

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.

Authors:

Robert Jotte Federico Cappuzzo Ihor Vynnychenko Daniil Stroyakovskiy Delvys Rodríguez-Abreu Maen Hussein Ross Soo Henry J Conter Toshiyuki Kozuki Kuan-Chieh Huang Vilma Graupner Shawn W Sun Tien Hoang Helen Jessop Mark McCleland Marcus Ballinger Alan Sandler Mark A Socinski

J Thorac Oncol 2020 08 14;15(8):1351-1360. Epub 2020 Apr 14.

Department of Thoracic Oncology, AdventHealth Cancer Institute, Orlando, Florida.

View Article and Find Full Text PDF

August 2020

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

ESMO Open 2020 01;5(1)

Medical Oncology, Centre Leon Berard, Lyon, France.

View Article and Find Full Text PDF

January 2020

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations.

Authors:

Martin Reck Geetha Shankar Anthony Lee Shelley Coleman Mark McCleland Vassiliki A Papadimitrakopoulou Mark A Socinski Alan Sandler

Expert Rev Respir Med 2020 02 12;14(2):125-136. Epub 2019 Dec 12.

Product Development Oncology, Genentech Inc, South San Francisco, CA, USA.

View Article and Find Full Text PDF

February 2020

A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

Authors:

Liza C Villaruz Manuel Cobo Konstantinos Syrigos Dimitrios Mavroudis Wei Zhang Jong Seok Kim Mark A Socinski

Lung Cancer 2019 10 14;136:52-56. Epub 2019 Aug 14.

UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

October 2019

Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.

Authors:

Daniel Morgensztern Amy Ko Mary O'Brien Teng Jin Ong Saiama N Waqar Mark A Socinski Pieter E Postmus Rafia Bhore

Cancer 2019 07 1;125(14):2394-2399. Epub 2019 Apr 1.

Celgene Corporation, Summit, New Jersey.

View Article and Find Full Text PDF

July 2019

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Lancet Respir Med 2019 05 25;7(5):387-401. Epub 2019 Mar 25.

AdventHealth Cancer Institute, Orlando, FL, USA.

View Article and Find Full Text PDF

May 2019

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Authors:

Qingyuan Huang Hua Zhang Josephine Hai Mark A Socinski Eric Lim Haiquan Chen Justin Stebbing

Oncoimmunology 2018;7(12):e1396403. Epub 2018 Jun 20.

Department of Surgery and Cancer, Imperial College London, London, UK.

View Article and Find Full Text PDF

June 2018

Atezolizumab Treatment of Nonsquamous NSCLC.

Authors:

Martin Reck Robert M Jotte Mark A Socinski

N Engl J Med 2018 09;379(12):1188

Florida Hospital Cancer Institute, Orlando, FL

View Article and Find Full Text PDF

September 2018

Patient-reported outcomes in a phase II, North American study of alectinib in patients with -positive, crizotinib-resistant, non-small cell lung cancer.

Authors:

Sai-Hong Ignatius Ou Mark A Socinski Shirish Gadgeel Leena Gandhi Howard West Alberto Alejandro Chiappori Victor Cohen Gregory J Riely Vlatka Smoljanovic Walter Bordogna Elaine Wright Kendra Debusk Ali Zeaiter Alice T Shaw

ESMO Open 2018 12;3(5):e000364. Epub 2018 Jul 12.

Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article and Find Full Text PDF

July 2018

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.

Authors:

Cesare Gridelli Tianlei Chen Amy Ko Mary E O'Brien Teng Jin Ong Mark A Socinski Pieter E Postmus

Drug Des Devel Ther 2018 24;12:1445-1451. Epub 2018 May 24.

Pulmonary Diseases, Clatterbridge Cancer Center, Liverpool, UK.

View Article and Find Full Text PDF

December 2018

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

N Engl J Med 2018 Jun 4;378(24):2288-2301. Epub 2018 Jun 4.

From the Florida Hospital Cancer Institute, Orlando (M.A.S.); Rocky Mountain Cancer Centers, Denver (R.M.J.); US Oncology, Houston (R.M.J.); Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy (F.C.); Instituto Nacional del Torax, Santiago, Chile (F.O.); Moscow City Oncology Hospital, Moscow (D.S.); National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan (N.N.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain (D.R.-A.); Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble (D.M.-S.), and Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - both in France; New England Cancer Specialists, Scarborough, ME (C.A.T.); Allegheny Health Network Cancer Institute, Pittsburgh (G.F.); Genentech, South San Francisco, CA (C.K., A.L., S.C., Y.D., Y.S., M.K., A.L.-C., A.S.); and Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.).

View Article and Find Full Text PDF

June 2018

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Clin Lung Cancer 2018 07 21;19(4):331-339. Epub 2018 Mar 21.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article and Find Full Text PDF

July 2018

Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.

Authors:

Martin Reck Marina Chiara Garassino Martina Imbimbo Frances A Shepherd Mark A Socinski Jin-Yuan Shih Anne Tsao Pablo Lee Katherine B Winfree Andreas Sashegyi Rebecca Cheng Rocio Varea Benjamin Levy Edward Garon

Lung Cancer 2018 06 27;120:62-69. Epub 2018 Mar 27.

David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network, Los Angeles, CA, USA.

View Article and Find Full Text PDF

June 2018

Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:

Juneko E Grilley-Olson Jared Weiss Anastasia Ivanova Liza C Villaruz Dominic T Moore Thomas E Stinchcombe Carrie Lee Joseph S Shan Mark A Socinski

Clin Lung Cancer 2018 07 17;19(4):e481-e487. Epub 2018 Mar 17.

University of Pittsburgh, Pittsburgh, PA.

View Article and Find Full Text PDF

July 2018

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Authors:

Matthew A Gubens Jody C Chuang Wallace Akerley Corey J Langer Christelle Clément-Duchêne Melanie San Pedro-Salcedo A Dimitrios Colevas Konstantin Dragnev Mark A Socinski Heather A Wakelee

J Thorac Dis 2018 Jan;10(1):219-227

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.

View Article and Find Full Text PDF

January 2018

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Lung Cancer 2018 03 3;117:44-49. Epub 2018 Feb 3.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.

View Article and Find Full Text PDF

March 2018

Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.

Authors:

Casey Mason Peter G Ellis Kathy Lokay Amanda Barry Natalie Dickson Ray Page Blase Polite Ravi Salgia Michael Savin Corey Shamah Mark A Socinski

J Clin Pathw 2018 Jan-Feb;4(1):49-54

Florida Hospital Cancer Institute, Orlando, FL.

View Article and Find Full Text PDF

August 2019

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Authors:

Helena A Yu Myung-Ju Ahn Byoung Chul Cho David E Gerber Ronald B Natale Mark A Socinski Nagdeep Giri Susan Quinn Eric Sbar Hui Zhang Giuseppe Giaccone

Lung Cancer 2017 10 23;112:195-199. Epub 2017 Aug 23.

Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road Washington DC 20007, USA. Electronic address:

View Article and Find Full Text PDF

October 2017

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Authors:

Mark A Socinski Coleman Obasaju David Gandara Fred R Hirsch Philip Bonomi Paul A Bunn Edward S Kim Corey J Langer Ronald B Natale Silvia Novello Luis Paz-Ares Maurice Pérol Martin Reck Suresh S Ramalingam Craig H Reynolds David R Spigel Heather Wakelee Nick Thatcher

J Thorac Oncol 2018 02 23;13(2):165-183. Epub 2017 Nov 23.

The Christie Hospital, Manchester, United Kingdom.

View Article and Find Full Text PDF

February 2018

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

Authors:

Carlo Genova Mark A Socinski Rebecca R Hozak Gu Mi Raffael Kurek Javad Shahidi Luis Paz-Ares Nick Thatcher Christopher J Rivard Marileila Varella-Garcia Fred R Hirsch

J Thorac Oncol 2018 02 20;13(2):228-236. Epub 2017 Nov 20.

Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address:

View Article and Find Full Text PDF

February 2018

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.

Authors:

Tudor Ciuleanu Mark A Socinski Coleman Obasaju Alexander V Luft Aleksandra Szczesna Wojciech Szafrański Rodryg Ramlau Beatrix Bálint Olivier Molinier Henrik Depenbrock Shivani Nanda Luis Paz-Ares Nick Thatcher

Clin Lung Cancer 2018 03 13;19(2):130-138.e2. Epub 2017 Oct 13.

Medical Oncology, The Christie Hospital, Manchester, UK.

View Article and Find Full Text PDF

March 2018

-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

Authors:

Michael Thomas David R Spigel Robert M Jotte Michael McCleod Mark A Socinski Ray D Page Laurent Gressot Jeanna Knoble Oscar Juan Daniel Morgensztern Dolores Isla Edward S Kim Howard West Amy Ko Teng Jin Ong Nataliya Trunova Cesare Gridelli

Lung Cancer (Auckl) 2017 30;8:207-216. Epub 2017 Oct 30.

Department of Oncology/Hematology, S.G. Moscati Hospital, Avellino, Italy.

View Article and Find Full Text PDF

October 2017

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.

Authors:

Katerina Ancevski Hunter Mark A Socinski Liza C Villaruz

Mol Diagn Ther 2018 02;22(1):1-10

University of Pittsburgh Cancer Institute, 5150 Centre Ave, Pittsburgh, PA, 15232, USA.

View Article and Find Full Text PDF

February 2018

Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.

Authors:

Kyle Wang Kevin A Pearlstein Nicholas D Patchett Allison M Deal Panayiotis Mavroidis Brian C Jensen Matthew B Lipner Timothy M Zagar Yue Wang Carrie B Lee Michael J Eblan Julian G Rosenman Mark A Socinski Thomas E Stinchcombe Lawrence B Marks

Radiother Oncol 2017 11 16;125(2):293-300. Epub 2017 Oct 16.

Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, United States.

View Article and Find Full Text PDF

November 2017

How I treat stage IV non-small cell lung cancer in the absence of any actionable oncogenic driver.

Authors:

Mark A Socinski

Clin Adv Hematol Oncol 2017 Oct;15(10):759-765

Florida Hospital Cancer Institute, Orlando, Florida.

View Article and Find Full Text PDF

October 2017

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Authors:

Federica Grosso Nicola Steele Silvia Novello Anna K Nowak Sanjay Popat Laurent Greillier Thomas John Natasha B Leighl Martin Reck Paul Taylor David Planchard Jens Benn Sørensen Mark A Socinski Ute von Wangenheim Arsène Bienvenu Loembé José Barrueco Nassim Morsli Giorgio Scagliotti

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article and Find Full Text PDF

November 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article and Find Full Text PDF

June 2017

Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

Authors:

Thomas E Stinchcombe Ying Zhang Everett E Vokes Joan H Schiller Jeffrey D Bradley Karen Kelly Walter J Curran Steven E Schild Benjamin Movsas Gerald Clamon Ramaswamy Govindan George R Blumenschein Mark A Socinski Neal E Ready Wallace L Akerley Harvey J Cohen Herbert H Pang Xiaofei Wang

J Clin Oncol 2017 Sep 11;35(25):2885-2892. Epub 2017 May 11.

Thomas E. Stinchcombe, Neal E. Ready, and Harvey J. Cohen, Duke University Medical Center; Xiaofei Wang, Alliance Statistics and Data Center, Durham, NC; Ying Zhang, Pennsylvania State University College of Medicine, Hershey, PA; Everett E. Vokes, University of Chicago Medical Center, Chicago, IL; Joan H. Schiller, Inova Dwight and Martha Schar Cancer Institute, Falls Church, VA; Jeffrey D. Bradley and Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Karen Kelly, University of California Davis, Sacramento, CA; Walter J. Curran Jr, Winship Cancer Institute of Emory University, Atlanta, GA; Steven E. Schild, Mayo Clinic Arizona, Scottsdale, AZ; Benjamin Movsas, Henry Ford Health System, Detroit, MI; Gerald Clamon, University of Iowa Hospital and Clinics, Iowa City, IA; George R. Blumenschein, University of Texas MD Anderson Cancer Center, Houston, TX; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Wallace L. Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; and Herbert H. Pang, University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.

View Article and Find Full Text PDF

September 2017

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Authors:

Ahmad A Tarhini Imran Rafique Theofanis Floros Phu Tran William E Gooding Liza C Villaruz Timothy F Burns David M Friedland Daniel P Petro Mariya Farooqui Jose Gomez-Garcia Autumn Gaither-Davis Sanja Dacic Athanassios Argiris Mark A Socinski Laura P Stabile Jill M Siegfried

Cancer 2017 Aug 4;123(15):2936-2944. Epub 2017 May 4.

Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.

View Article and Find Full Text PDF

August 2017

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.

Authors:

Mark A Socinski Frederic J Kaye David R Spigel Fred J Kudrik Santiago Ponce Peter M Ellis Margarita Majem Paul Lorigan Leena Gandhi Martin E Gutierrez Dale Nepert Jesus Corral Luis Paz Ares

Clin Lung Cancer 2017 01 3;18(1):68-76.e2. Epub 2016 Oct 3.

Medical Oncology Department, Hospital Universitario 12 de Octubre and Lung Cancer Unit CNIO, Madrid, Spain.

View Article and Find Full Text PDF

January 2017

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Authors:

Mark M Awad Quincy S-C Chu Leena Gandhi Joe J Stephenson Ramaswamy Govindan Daniel S Bradford Philip D Bonomi David M Ellison Keith D Eaton Holger Fritsch Gerd Munzert Bruce E Johnson Mark A Socinski

Lung Cancer 2017 02 30;104:126-130. Epub 2016 Dec 30.

University of Pittsburgh, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

February 2017

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

JAMA Oncol 2017 Aug;3(8):1043-1050

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF

August 2017

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

Authors:

Mark A Socinski Jamie E Chaft Benjamin Levy Gregory J Riely Corey J Langer Roman Perez-Soler Deborah L Middleton Linda Gracie-King Laura M Healy

Clin Lung Cancer 2017 05 5;18(3):255-258. Epub 2017 Jan 5.

AXIS Medical Education, Fort Lauderdale, FL.

View Article and Find Full Text PDF

May 2017

Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer.

Authors:

Mark E Bernard Scott M Glaser Beant S Gill Sushil Beriwal Dwight E Heron James D Luketich David M Friedland Mark A Socinski Joel S Greenberger

Front Oncol 2017 23;7. Epub 2017 Jan 23.

Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.

View Article and Find Full Text PDF

January 2017

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).

Authors:

Maria Q Baggstrom Mark A Socinski Xiaofei F Wang Lin Gu Thomas E Stinchcombe Martin J Edelman Sherman Baker Josephine Feliciano Paul Novotny Olwen Hahn Jeffrey A Crawford Everett E Vokes

J Thorac Oncol 2017 05 1;12(5):843-849. Epub 2017 Feb 1.

Division of Oncology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.

View Article and Find Full Text PDF

May 2017

Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

Authors:

Kyle Wang Michael J Eblan Allison M Deal Matthew Lipner Timothy M Zagar Yue Wang Panayiotis Mavroidis Carrie B Lee Brian C Jensen Julian G Rosenman Mark A Socinski Thomas E Stinchcombe Lawrence B Marks

J Clin Oncol 2017 May 23;35(13):1387-1394. Epub 2017 Jan 23.

Kyle Wang, Michael J. Eblan, Matthew Lipner, Timothy M. Zagar, Panayiotis Mavroidis, Carrie B. Lee, Brian C. Jensen, Julian G. Rosenman, and Lawrence B. Marks, University of North Carolina Hospitals; Allison M. Deal and Yue Wang, Lineberger Comprehensive Cancer Center Biostatistics Core, University of North Carolina Hospitals, Chapel Hill; Thomas E. Stinchcombe, Duke University Hospitals, Durham, NC; and Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL.

View Article and Find Full Text PDF

May 2017

Paradoxical functions of ZEB1 in -mutant lung cancer: tumor suppressor and driver of therapeutic resistance.

Authors:

Zachary A Yochum Mark A Socinski Timothy F Burns

J Thorac Dis 2016 Nov;8(11):E1528-E1531

Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA;; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

November 2016

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article and Find Full Text PDF

December 2016

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

Authors:

Mark A Socinski Nathan A Pennell

Cancer Control 2016 Oct;23(4 Suppl):2-14

Florida Hospital Cancer Institute, Orlando, FL, USA.

View Article and Find Full Text PDF

October 2016

Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.

Authors:

Mark A Socinski Liza C Villaruz Jeffrey Ross

Oncologist 2017 01 7;22(1):3-11. Epub 2016 Nov 7.

Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article and Find Full Text PDF

January 2017

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.

Authors:

Corey J Langer Coleman Obasaju Paul Bunn Philip Bonomi David Gandara Fred R Hirsch Edward S Kim Ronald B Natale Silvia Novello Luis Paz-Ares Maurice Pérol Martin Reck Suresh S Ramalingam Craig H Reynolds Mark A Socinski David R Spigel Heather Wakelee Carlos Mayo Nick Thatcher

J Thorac Oncol 2016 12 26;11(12):2066-2081. Epub 2016 Aug 26.

The Christie Hospital, Manchester, United Kingdom.

View Article and Find Full Text PDF

December 2016

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).

Authors:

Martin Reck Michael Thomas Cornelia Kropf-Sanchen Jörg Mezger Mark A Socinski Henrik Depenbrock Victoria Soldatenkova Jacqueline Brown Thomas Krause Nick Thatcher

Oncol Res Treat 2016 2;39(9):539-47. Epub 2016 Aug 2.

Department of Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research (DZL), German Center for Lung Research (DZL), LungenClinic Grosshansdorf, Grosshansdorf, Germany.

View Article and Find Full Text PDF

April 2017

Immune checkpoint blockade in lung cancer.

Authors:

Aswin Somasundaram Mark A Socinski Liza C Villaruz

Discov Med 2016 08;22(119):55-65

Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article and Find Full Text PDF

August 2016

HSP90 inhibitors in lung cancer: promise still unfulfilled.

Authors:

Suman Chatterjee Saveri Bhattacharya Mark A Socinski Timothy F Burns

Clin Adv Hematol Oncol 2016 May;14(5):346-56

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

May 2016

Clinicopathologic Features of Advanced Squamous NSCLC.

J Thorac Oncol 2016 09 11;11(9):1411-22. Epub 2016 Jun 11.

The Christie Hospital, Manchester, United Kingdom.

View Article and Find Full Text PDF

September 2016

Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.

Authors:

Vera Hirsh Amy Ko Richard Pilot Markus F Renschler Mark A Socinski

Clin Lung Cancer 2016 09 22;17(5):367-374. Epub 2016 Apr 22.

University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article and Find Full Text PDF

September 2016

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Authors:

David Planchard Tae Min Kim Julien Mazieres Elisabeth Quoix Gregory Riely Fabrice Barlesi Pierre-Jean Souquet Egbert F Smit Harry J M Groen Ronan J Kelly B C Cho Mark A Socinski Lini Pandite Christine Nase Bo Ma Anthony D'Amelio Bijoyesh Mookerjee C Martin Curtis Bruce E Johnson

Lancet Oncol 2016 05 11;17(5):642-50. Epub 2016 Apr 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article and Find Full Text PDF

May 2016

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.

Authors:

Martin Reck Mark A Socinski Alexander Luft Aleksandra Szczęsna Mircea Dediu Rodryg Ramlau György Losonczy Olivier Molinier Christian Schumann Richard J Gralla Philip Bonomi Jacqueline Brown Victoria Soldatenkova Nadia Chouaki Coleman Obasaju Patrick Peterson Nick Thatcher

J Thorac Oncol 2016 Jun 12;11(6):808-18. Epub 2016 Mar 12.

The Christie Hospital, Manchester, United Kingdom.

View Article and Find Full Text PDF

June 2016

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.

Authors:

Liza C Villaruz Mark A Socinski

Eur J Cancer 2016 Mar 12;56:162-171. Epub 2016 Feb 12.

University of Pittsburgh Cancer Institute, Lung Cancer Program, 5150 Center Avenue, Pittsburgh, PA 15232, USA. Electronic address:

View Article and Find Full Text PDF

March 2016

Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.

Authors:

Jared M Weiss Liza C Villaruz Jonathon O'Brien Anastasia Ivanova Carrie Lee Juneko Grilley Olson Gregory Pollack Richard Gorman Mark A Socinski Thomas E Stinchombe

Clin Lung Cancer 2016 Mar 17;17(2):128-32. Epub 2015 Dec 17.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.

View Article and Find Full Text PDF

March 2016

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Lancet Oncol 2016 Feb 19;17(2):234-242. Epub 2015 Dec 19.

Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA, USA.

View Article and Find Full Text PDF

February 2016

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.

Authors:

Diwakar Davar Mark A Socinski Sanja Dacic Timothy F Burns

Exp Hematol Oncol 2015 14;4:34. Epub 2015 Dec 14.

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA USA ; Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Office: Suite 2.18e, Pittsburgh, PA 15232 USA.

View Article and Find Full Text PDF

December 2015

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.

Authors:

Saveri Bhattacharya Mark A Socinski Timothy F Burns

Clin Transl Med 2015 Dec 14;4(1):35. Epub 2015 Dec 14.

University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Office: Suite 2.18e, Pittsburgh, PA, 15232, USA.

View Article and Find Full Text PDF

December 2015

Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.

Authors:

Mark A Socinski

Semin Oncol 2015 Oct 11;42 Suppl 2:S19-28. Epub 2015 Sep 11.

Co-Leader, UPCI Lung Cancer Program, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address:

View Article and Find Full Text PDF

October 2015

Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.

Authors:

Mark A Socinski

Semin Oncol 2015 Oct 11;42 Suppl 2:S1-2. Epub 2015 Sep 11.

Co-Leader, UPCI Lung Cancer Program University of Pittsburgh Medical Center Pittsburgh, PA.

View Article and Find Full Text PDF

October 2015

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.

Authors:

Primo N Lara Jeff Longmate Philip C Mack Karen Kelly Mark A Socinski Ravi Salgia Barbara Gitlitz Tianhong Li Mariana Koczywas Karen L Reckamp David R Gandara

Clin Cancer Res 2015 Oct 23;21(19):4321-6. Epub 2015 Jun 23.

University of California Davis Comprehensive Cancer Center, Sacramento, California.

View Article and Find Full Text PDF

October 2015

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Lancet Oncol 2015 Jul 1;16(7):763-74. Epub 2015 Jun 1.

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

July 2015

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.

Authors:

Roberto Gomez-Casal Chitralekha Bhattacharya Michael W Epperly Per H Basse Hong Wang Xinhui Wang David A Proia Joel S Greenberger Mark A Socinski Vera Levina

Cancers (Basel) 2015 May 22;7(2):876-907. Epub 2015 May 22.

The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.

View Article and Find Full Text PDF

May 2015

The role of anti-angiogenesis in non-small-cell lung cancer: an update.

Authors:

Liza C Villaruz Mark A Socinski

Curr Oncol Rep 2015 Jun;17(6):26

Lung Cancer Program, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 5th Floor Cancer Pavilion, Room 567, Pittsburgh, PA, 15232, USA,

View Article and Find Full Text PDF

June 2015

Immunotherapy in lung cancer.

Authors:

Liza C Villaruz Aparna Kalyan Hassane Zarour Mark A Socinski

Transl Lung Cancer Res 2014 Feb;3(1):2-14

University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, USA.

View Article and Find Full Text PDF

February 2014

Highlights in NSCLC from the 2014 ASCO meeting.

Authors:

Mark A Socinski

Clin Adv Hematol Oncol 2014 Oct;12(10 Suppl 18):16-9

University of Pittsburgh, Pittsburgh, Pennsylvani.

View Article and Find Full Text PDF

October 2014

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Lancet Oncol 2015 Mar 18;16(3):328-37. Epub 2015 Feb 18.

University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

March 2015

Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancer.

Authors:

Mark A Socinski

Clin Adv Hematol Oncol 2014 Nov;12(11):763, 767-8

University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article and Find Full Text PDF

November 2014

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.

Authors:

Corey J Langer Mark A Socinski Jyoti D Patel Alan B Sandler Joan H Schiller Larry Leon Sebastien J Hazard Suresh S Ramalingam

Am J Clin Oncol 2016 10;39(5):441-7

*Abramson Cancer Center, University of Pennsylvania, Philadelphia †University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA ‡Feinberg School of Medicine, Northwestern University, Chicago, IL §Genentech Inc., South San Francisco, CA ∥Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX ¶Winship Cancer Institute of Emory University, Atlanta, GA.

View Article and Find Full Text PDF

October 2016

Clinical considerations for the development of biosimilars in oncology.

Authors:

Mark A Socinski Giuseppe Curigliano Ira Jacobs Barry Gumbiner Judith MacDonald Dolca Thomas

MAbs 2015 ;7(2):286-93

a University of Pittsburgh ; Pittsburgh , PA USA.

View Article and Find Full Text PDF

November 2015

A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.

Authors:

Juneko E Grilley-Olson Vicki L Keedy Alan Sandler Dominic T Moore Mark A Socinski Thomas E Stinchcombe

Oncologist 2015 Feb 23;20(2):105-6. Epub 2015 Jan 23.

Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA;

View Article and Find Full Text PDF

February 2015

Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Authors:

David R Spigel Jyoti D Patel Craig H Reynolds Edward B Garon Robert C Hermann Ramaswamy Govindan Mark R Olsen Katherine B Winfree Jian Chen Jingyi Liu Susan C Guba Mark A Socinski Philip Bonomi

J Thorac Oncol 2015 Feb;10(2):353-9

*Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; †Feinberg School of Medicine, Northwestern University, Chicago, IL; ‡Ocala Oncology, Ocala, FL and US Oncology Research, Inc., Houston, TX; §David Geffen School of Medicine at UCLA/Translational Research in Oncology-US, Los Angeles, CA; ║Northwest Georgia Oncology Centers, Marietta, GA; ¶Washington University School of Medicine, St. Louis, MO; #Tulsa Cancer Institute, Tulsa, OK; **Eli Lilly and Company, Indianapolis, IN; ††University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and ‡‡Rush University Medical Center, Chicago, IL.

View Article and Find Full Text PDF

February 2015

Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.

Authors:

Gary Spitzer Mark A Socinski

J Clin Oncol 2015 Feb 12;33(5):522-3. Epub 2015 Jan 12.

University of Pittsburgh Schools of the Health Sciences, Pittsburgh, PA.

View Article and Find Full Text PDF

February 2015

Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.

Authors:

Corey J Langer Vera Hirsh Amy Ko Markus F Renschler Mark A Socinski

Clin Lung Cancer 2015 Mar 30;16(2):112-20. Epub 2014 Sep 30.

University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article and Find Full Text PDF

March 2015

Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

Authors:

Shakun M Malik Richard Pazdur Jeffrey S Abrams Mark A Socinski William T Sause David H Harpole John J Welch Edward L Korn Claudio Dansky Ullmann Fred R Hirsch

J Thorac Oncol 2014 Oct;9(10):1443-8

*Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; †Offices of Hematology and Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, MD; ‡University of Pittsburgh Medical Center, Pittsburgh, PA; §University of Utah, Salt Lake City, UT; ‖Duke University Medical Center, Durham, NC; ¶Biometric Research Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; and #University of Colorado, School of Medicine, Denver, CO.

View Article and Find Full Text PDF

October 2014

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.

Authors:

Craig H Reynolds Jyoti D Patel Edward B Garon Mark R Olsen Philip Bonomi Ramaswamy Govindan Eduardo J Pennella Jingyi Liu Susan C Guba Shi Li David R Spigel Robert C Hermann Mark A Socinski Coleman K Obasaju

Clin Lung Cancer 2015 May 18;16(3):200-8. Epub 2014 Nov 18.

Eli Lilly and Company, Indianapolis, IN.

View Article and Find Full Text PDF

May 2015

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

Authors:

Joachim von Pawel Robert Jotte David R Spigel Mary E R O'Brien Mark A Socinski Jörg Mezger Martin Steins Léon Bosquée Jeffrey Bubis Kristiaan Nackaerts José M Trigo Philip Clingan Wolfgang Schütte Paul Lorigan Martin Reck Manuel Domine Frances A Shepherd Shaoyi Li Markus F Renschler

J Clin Oncol 2014 Dec 10;32(35):4012-9. Epub 2014 Nov 10.

Joachim von Pawel, Asklepios Fachkliniken München-Gauting, Gauting; Jörg Mezger, St Vincentius-Kliniken Karlsruhe, Karlsruhe; Martin Steins, Thoraxklinik am Universitätsklinikum, Heidelberg; Wolfgang Schütte, Krankenhaus Martha-Maria Halle-Dölau, Halle; Martin Reck, Krankenhaus Großhansdorf, Großhansdorf, Germany; Robert Jotte, Rocky Mountain Cancer Center, Denver, CO, and US Oncology, Houston, TX; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Mary E.R. O'Brien, Royal Marsden National Health Service (NHS) Foundation Trust, Surrey; Paul Lorigan, Christie NHS Foundation Trust, Manchester, United Kingdom; Mark A. Socinski, University of Pittsburgh Medical Center, Pittsburgh, PA; Léon Bosquée, Centre Hospitalier Universitaire Sart-Tilman, Liège; Kristiaan Nackaerts, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Jeffrey Bubis, Cancer Specialists of North Florida, Jacksonville, FL; José M. Trigo, Hospital Universitario Virgen de la Victoria, Malaga; Manuel Domine, Fundación Jiménez Diaz, Universidad Autónoma de Madrid, Madrid, Spain; Philip Clingan, Southern Medical Day Care Centre, Wollongong, New South Wales, Australia; Frances A. Shepherd, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Shaoyi Li and Markus F. Renschler, Celgene, Summit, NJ.

View Article and Find Full Text PDF

December 2014

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

Authors:

Aswin Somasundaram Mark A Socinski Timothy F Burns

Expert Opin Pharmacother 2014 Dec 10;15(18):2693-708. Epub 2014 Nov 10.

Lung Cancer Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.

View Article and Find Full Text PDF

December 2014

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authors:

Liza C Villaruz Mark A Socinski Shira Abberbock Lynne D Berry Bruce E Johnson David J Kwiatkowski A John Iafrate Marileila Varella-Garcia Wilbur A Franklin D Ross Camidge Lecia V Sequist Eric B Haura Mark Ladanyi Brenda F Kurland Kelly Kugler John D Minna Paul A Bunn Mark G Kris

Cancer 2015 Feb 1;121(3):448-56. Epub 2014 Oct 1.

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

February 2015

A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.

Authors:

Jared M Weiss Liza C Villaruz Mark A Socinski Anastasia Ivanova Juneko Grilley-Olson Nirav Dhruva Thomas E Stinchcombe

Lung Cancer 2014 Nov 26;86(2):288-90. Epub 2014 Aug 26.

University of North Carolina at Chapel Hill, 170 Manning Drive, Physician's Office Building 3rd Floor, Chapel Hill, NC 27599-7305, United States. Electronic address:

View Article and Find Full Text PDF

November 2014

Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Authors:

Joel L Weissfeld Brenda Diergaarde Tomoko Nukui Shama Buch Arjun Pennathur Mark A Socinski Jill M Siegfried Marjorie Romkes

J Thorac Oncol 2014 Sep;9(9):1264-71

*University of Pittsburgh Cancer Institute and †Department of Epidemiology, University of Pittsburgh Graduate School of Public Health; ‡Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine; §Department of Medicine, University of Pittsburgh School of Medicine; ‖Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; ¶Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA.

View Article and Find Full Text PDF

September 2014

Metastasis of breast carcinoma to the maxillary sinus.

Authors:

José Pablo Leone Saveri Bhattacharya Mark A Socinski Adam Sohnen Simion Chiosea Shannon Puhalla Adam Brufsky

Breast J 2014 May-Jun;20(3):318-9. Epub 2014 Apr 2.

Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

May 2015

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

Authors:

Rebecca S Heist Xiaofei Wang Lydia Hodgson Gregory A Otterson Thomas E Stinchcombe Leena Gandhi Miguel A Villalona-Calero Peter Watson Everett E Vokes Mark A Socinski

J Thorac Oncol 2014 Feb;9(2):214-21

*Department of Thoracic Oncology, Massachusetts General Hospital, Boston, Massachusetts; †Department of Oncology, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina; ‡Department of Oncology, Ohio State University Medical Center, Columbus, Ohio; §Department of Oncology, University of North Carolina, Chapel Hill, North Carolina; ‖Department of Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, Kinston Medical Specialists, P.A., Kinston, North Carolina; #Department of Oncology, University of Chicago, Chicago, Illinois; and **Department of Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

February 2014

Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.

Authors:

Friedrich D Knollmann Rohan Kumthekar David Fetzer Mark A Socinski

Clin Lung Cancer 2014 Mar 13;15(2):103-9. Epub 2013 Nov 13.

University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA.

View Article and Find Full Text PDF

March 2014

Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.

Authors:

Liza C Villaruz Mark A Socinski

Lung Cancer 2014 Feb 1;83(2):300-1. Epub 2013 Dec 1.

University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States.

View Article and Find Full Text PDF

February 2014

RET rearrangements in lung adenocarcinoma and radiation.

Authors:

Sanja Dacic Alyssa Luvison Viktoria Evdokimova Lindsey Kelly Jill M Siegfried Liza C Villaruz Mark A Socinski Yuri E Nikiforov

J Thorac Oncol 2014 Jan;9(1):118-20

Departments of *Pathology, †Pharmacology, University of Pittsburgh; and 3University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

January 2014

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

Authors:

Vera Hirsh Isamu Okamoto Jeremy K Hon Ray D Page James Orsini Hiroshi Sakai Hui Zhang Markus F Renschler Mark A Socinski

J Thorac Oncol 2014 Jan;9(1):83-90

*McGill University, Montreal, Quebec, Canada; †Kinki University Faculty of Medicine, Osaka-Sayama, Japan; ‡Clearview Cancer Institute, Huntsville, Alabama; §The Center for Cancer and Blood Disorders, Fort Worth, Texas; ‖Essex Oncology of New Jersey, Belleville, New Jersey; ¶Saitama Cancer Center, Saitama, Japan; #Celgene Corporation, Summit, New Jersey; and **University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

January 2014

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Lancet Oncol 2014 Jan 9;15(1):59-68. Epub 2013 Dec 9.

University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article and Find Full Text PDF

January 2014

Do oncogenic drivers exist in squamous cell carcinoma of the lung?

Authors:

Liza C Villaruz Timothy F Burns Mark A Socinski

Oncology (Williston Park) 2013 Sep;27(9):906, 913-4

University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

September 2013

Personalizing therapy in advanced non-small cell lung cancer.

Authors:

Liza C Villaruz Timothy F Burns Vasilis S Ramfidis Mark A Socinski

Semin Respir Crit Care Med 2013 Dec 20;34(6):822-36. Epub 2013 Nov 20.

Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article and Find Full Text PDF

December 2013

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Authors:

Jyoti D Patel Mark A Socinski Edward B Garon Craig H Reynolds David R Spigel Mark R Olsen Robert C Hermann Robert M Jotte Thaddeus Beck Donald A Richards Susan C Guba Jingyi Liu Bente Frimodt-Moller William J John Coleman K Obasaju Eduardo J Pennella Philip Bonomi Ramaswamy Govindan

J Clin Oncol 2013 Dec 21;31(34):4349-57. Epub 2013 Oct 21.

Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO.

View Article and Find Full Text PDF

December 2013